JiangsuHengruiPharmaceuticalsandKailera Therapeutics have reported positive topline data from Hengrui's Phase II obesity trial, considering an 8mg dose of the companies' GLP-1/GIP receptor ...
Oct 10, 2024Ropes & Gray advised Kailera Therapeutics, Inc. and its investors on the establishment of the company, its $400 million Series A financing, and the worldwide (ex-China) licensing by the company of a portfolio of clinical-stage metabolic disease assets from HengruiPharmaceuticals, a leading Chinese pharmaceutical company.
In one of the top series A financings in biopharma history, new company Kailera Therapeutics Inc. emerged with $400 million raised and a pipeline of next-generation assets to treat obesity and type 2 diabetes.
Oct 10, 2024In May 2024, HengruiPharmaceutical, a leading global pharmaceutical company listed on the Shanghai Stock Exchange (600276.SH), announced that it had granted exclusive rights to develop, manufacture, and commercialize its proprietary GLP-1 class of drugs—HRS-7535, HRS-9531, and HRS-4729—to Hercules. ... now renamed Kailera Therapeutics ...
Oct 1, 2024Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $400 million in early-stage funding.
May 20, 2024For HengruiPharmaceutical, the recent developments have been a mix of highs and lows.. On the evening of the 16th, Hengrui announced a collaboration deal: granting Hercules Pharmaceuticals (USA) the global rights outside of Greater China for the development, production, and commercialization of its GLP-1 combination. Hence, Hengrui will receive a $100 million milestone payment and is eligible ...
Metabolic Meds Biotech Kailera Launches With $400M for Next-Generation Weight-Loss Drugs Kailera Therapeutics licensed its portfolio of metabolic disorder drugs from Hengrui.
Oct 1, 2024Headed by CEO Ron Renaud, who previously led Cerevel Therapeutics and oversaw its acquisition by AbbVie in an $8.7 billion deal last year, the company is developing several injectable and oral ...
Oct 1, 2024The investors have also brought in a familiar face: Ron Renaud, who recently oversaw the $8.7 billion acquisition of Cerevel Therapeutics, a spinout of Pfizer assets that Bain helped finance back ...
Can’t find what you’re looking for?
Help us improve DuckDuckGo searches with your feedback